SUMMARY
Introduction
Glaucoma is a chronic, progressive, heterogeneous optic neuropathy which leads to visual field loss, disabilities and irreversible blindness if not diagnosed and treated at the right time. Glaucoma firstly affects peripheral vision and secondly central vision. Since it is silent, chronic disease with no clinical signs at the beginning of illness, it is often undiagnosed and underestimated (Eramudugolla et al. 2013) . In many cases when diagnosed, glaucoma is already in advanced stage. Clinical trials confirmed the importance of intraocular pressure (IOP) in the development and progression of open-angle glaucoma, even if evidence suggests the existence of ocular and systemic factors, in addition to IOP, that can be responsible for this development and progression (Actis et al. 2016) . These various risk factors may be organized into various categories (Agorastos & Huber 2011, Nageeb & Kulkarni 2015): demographic (age, sex and race), lifestyle (smoking, alcohol), comorbidities (heart disease, peripheral hypertension, diabetes, obesity), ophthalmic risk factors (eye structure, central corneal thickness, corneal hysteresis, intraocular pressure, myopia, cataract, vascular abnormalities), family history, socioeconomic status and compliance (Salowe et al. 2015 ). The point is that the main risk factor is ocular pressure (it is also the only one we can treat today), then we can discuss upon the others. In general, patients with visual impairment have higher prevalence of psychological disturbance -such as depression, anxiety or sleep disorders (Agorastos et Spinelli et al. 1998 ). The level of depressive symptoms is higher in patients with multiple eye disease (Eramudugolla et al. 2013 , Pop-Jordanova et al. 2014 ). Dual sensory loss, such as visual and hearing impairment, increases even more the level of depressive symptoms (Kiely et al. 2013 ). On the other hand, depression is one of the most common psychological disturbances among patients that is comorbid with other chronic physical diseases in general (Jeong et al. 2016 , Moussavi et al. 2007 ) with the most negative effect on the health score. Depression has also higher prevalence among older population (Skalicky & Goldberg 2008) . The risk factors for the development of psychological disorders in glaucoma patients could be subjective and objective (Kong et al. 2014 ). The age, sex, visual field loss (VFL) and the severity of glaucoma condition are some of the objective risk factors on which the patients have no influence (Kong et al. 2014 ). The subjective risk factors, such as regular and proper administration of topical antiglaucoma medication, education and proper understanding of character of the glaucoma disease or adoption of healthy habits, could be influenced by patients. In the study among the Chinese patients, the comprehension of the character of glaucoma is an independent factor negatively related to psychological disturbance and positively related to the Quality of Life (QoL) among the glaucoma patients (Kong et al. 2014 ). The authors emphasize the value of education in establishing the healthy habits (the importance of compliance with the therapy) among the patients. The knowledge of glaucoma character with consequent understanding of the value of therapy compliance decreased psychological disturbance and contributed to the higher QoL. In the paper of Agorastos et al, visual field defects (VFD) were predictive factors of depression, anxiety and sleep disorder (Agorastos et al. 2013 ). The loss of everyday life abilities (driving the car, reading, moving indoors and outdoors, depending on the help of others) could be an important factor in developing depression in glaucoma patient.
Methodology
The literature search was performed by using PubMed and MEDLINE. The searched terms were "glaucoma", "depression", "glaucoma and depression", "quality of life and glaucoma". This mini review was limited to the articles published in English language. All types of relevant articles were included in the review, including the original research, reviews and other articles of interest. The additional relevant papers were added from the bibliography of selected paper. The time period was not defined.
Pathophysiology of glaucoma and depression
Ophthalmic risk factors for glaucoma onset and development are: first of all intraocular pressure (IOP), followed by eye structure (angle of the anterior chamber), central corneal thickness, myopia, cataract, and vascular abnormalities (Salowe 2015) . The important pathophysiological mechanism of glaucoma is redundant retinal oxidative stress (ROS) with the consequence on glaucomatous changes and neurodegeneration. The result is the loss of the intrinsically MLT has also an important role in the regulation of circadian rhythm by modulating electrical activities of neurons of suprachiasmatic nucleus. Changes in circadian system or chronodisruption can have an effect on sleep disturbance, seasonal affective disorders and depressive disorders . Pathophysiology of depression is not unique and clearly defined. It was shown that serotonin (Dell'Osso 2016), norepinephrine, glutamate and dopamine have an important role in pathophysiology of depressive disorders (Niciu et al. 2014 ). Recent researches indicate that MLT might have an important role in pathophysiology and possible therapy in many diseases, such as depression, diabetes, pain, neurodegenerative diseases, circadian and mood disorders, insomnia (Comai & Gobbi 2014) , and vision disorder such as glaucoma (Agorastos & Huber 2011 . MLT is synthesized from serotonin and acts through MT1 and MT2 receptors (Agorastos & Huber 2011 , Comai 2014 ). In the study of Comai and Gobi MT2 receptors were involved in the pathophysiology and pharmacology of depression (Comai & Gobbi 2014 ). In addition, MT1 and MT2 receptors were identified in mammalian retina ). Therefore, MLT might be connected with reducing of IOP . Pathophysiological connection between depression and glaucoma might origin from the reduced absorption of light because of retinal disruption which leads to irregular melatonin synthesis as it was showed in various animal models ). The result is higher prevalence of depression, anxiety, and sleep disorder.
There is no clear evidence of effectiveness of neuroprotective agents on progression of OAG (Sena & Lindlsey 2017 ). Further clinical researche should plan to explore the benefits of neuroprotective agents on OAG and preservation of vision.
Epidemiological data
The epidemiological studies indicated an increase in the prevalence of glaucoma . Glaucoma and macular degeneration global burden were overrepresented according to the Global burden of eye and vision disease as reflected in the Cochrane Database of Systematic Reviews (Boyers et al. 2015) . This finding might suggest that certain diseases such as glaucoma attract much more attention of researchers than others, because of their importance in causing morbidity and disabilities.
The results of Moussavis' research, World Health Study (WHS) by World Health Organization (WHO), showed that one-year prevalence of depressive episode was 3.2 % in the 60 countries involved in research (Moussavi et al. 2007 ). In the case of comorbid depression (depression with chronic physical disease) the prevalence was significantly higher, between 9.3% and 23.0%. Depressive disorders were the second leading cause of YLD according to Global Burden of Disease Study 2010 (Ferrari et al. 2013) as it was in the Japanese Clinical study (Mabuchi et al. 2012 ). The range of the prevalence of depression in glaucoma patients was between 11.4% and 32.1% in the Australian clinical study performed by Skalicky et and Goldberg (Skalicky & Goldberg 2008 ).
The quality of life of glaucoma patients with depression
The concept of QoL in the last decades has become the focus of interest of many physicians, especially those who treat the chronic disease patients (Labiris et al. 2011 ). To comprehend the concept of QoL and its purpose in diagnosing and treatment of patients, the researchers need to be aware of the parameters that comprise it: physical, functional, social, and psychological ( . As the last study indicated, two types of QoL instruments (general health and glaucoma-specific instruments) might be used to assess the proper Qol in glaucoma patients.
Assessment of depression in glaucoma patients
The analyzed literature in this paper provides an overview of instruments used for assessment of depression in glaucoma patients (Gothwal et . The screening of the depression like disorder, diagnose of the disorder, assessment of severity of disorder, and the measurement of changes in severity of disorders represent the main purpose of assessment of the scales for depression (Furukawa 2010 ). The psychiatric assessments can be organized in two formats: clinician-rated and self-report (Furukawa 2010) .
Hamilton Depression Rating Scale (HDRS) is clinician-rated scale with 21 items for assessing the severity and measuring the changes of depression (Furukawa 2010 , Cumurcu et al. 2014 ). Montgomeri-Asberg Depression Rating Scale (MADRS) is clinician-rated instrument created with the purpose of measuring the severity and changes of depression (Furukawa 2010 The purpose of PHQ-9 is self-reported screening of depression, measuring of severity and measuring of changes in depression. The responds are ranked based on the frequency of depressive symptoms over the previous two weeks. In the analyses of validity for screening PHQ-9 showed substantial heterogeneity which was not explained (Furukawa 2010 ). PHQ-9 provided suboptimal assessment of depression in glaucoma patients in India, in Study of Gothwal et al. (Gotwall et al. 2014 ).
Geriatric Depression Scale-15 (GDS-15) is selfreport instrument with 15 items used to assess depression in elderly population (Skalicky & Goldberg 2008 ).
Self-rating Depression Scale (SDS) is 20 item, selfreported scale, used to asses affective, psychological and somatic symptoms associated with depression. The responses are ranked according to the frequency of symptoms in the past several days (Kong et al. 2015 ).
Depression and glaucoma -studies
On the basis of the above mentioned scales, 11 studies were extracted in this review. The prevalence of depression in patients with visual impairment is the issue of research in many studies (Ayaki et . This study was primary designed for the assessment of prevalence of sleep and mood disorders in the eye clinic patients. The total number of participants was 730, only 109 of them were glaucoma patients (e.g. Table 1 ). The severity of glaucoma and older age of the patients, in the study of Skalicky and Goldberg, contributed to higher prevalence of depression in glaucoma patients (Skalicky & Goldberg 2008) . The purpose of this study was also to determinate the association of depression and the QoL in glaucoma patients. Glaucoma specific instrument Glaucoma Quality of life-15 (GQL-15) was used for the QoL assessment. The results showed decreased quality of life with worsening severity of glaucoma. The total number and share of glaucoma patients are shown in the table 1. The increasing trend of depression in this study might be due to decrease of central and peripheral vision with consequent reduction of subjective and objective visual function. In the study of Agorastos et al, the VFL in glaucoma was the principal predictive factor of depression (Agorastos et al. 2013 ) and other psychological disturbances. One of the main messages of this study is the necessity of screening for psychological disturbance and psychochronobiological treatment of glaucoma patients. The importance of regular screening for depression in glaucoma patients supports also the findings of the study of Pop-Jordanova et al, which show that depression was often unrecognized and untreated problem (Pop-Jordanova et al. 2014). The prevalence of depression was often higher in the patients with severe ophthalmological disturbances (glaucoma, age-related macular degeneration, proliferative diabetic retinopathy and cataract) in the study of Pop-Jordanova (PopJordanova et al. 2014) which is consistent with the study of Skalicky and Goldberg (Skalicky & Goldberg 2008) . In addition the level of depression was found higher in the elderly population which is in coincidence with both the above mentioned studies (Skalicky & Goldberg 2008 , Pop-Jordanova et al. 2014 ).
The two papers from this review reported comorbidity of specific type of glaucoma and depression (Cumurcu et al. 2006 , Kong et al. 2015 . The study of Cumurcu et al, discussed the association of pseudoexfoliative glaucoma (PXG) and depression (Cumurcu et al. 2006 ). The PXG patients were more depressed then patients with primary open angle glaucoma (POAG) and control group. The same study showed no significant differences in the anxiety scale comparing PXG or POAG group respectively, and the control groups. The higher level of depression was associated with the patients with primary angle closer glaucoma (PACG) in contrast to patients with POAG and control group in the study of Kong et al. (Kong et al. 2015) . Both studies compared POAG with other types of glaucoma and both studies showed that patients with POAG were less depressed. However, on the basis of these two studies, it could not be possible to conclude that POAG patients are less depressed than patients who suffer from other types of glaucoma. The existence of association of certain type of glaucoma and depression (Cumurcu et Finally, the last two studies from this review, which used PGQ-9 scale, did not have congruent results (Wang et al. 2012 , Gothwal et al. 2014 ). PHQ-9 instrument in the study of Gothwal et al. with 198 patients did not provide optimal assessment of depression in glaucoma patients (Gothwal et al. 2014 ). In the study of Wang et al. (2012) , where the PHQ-9 scale was also used, the presence of correlation between depression and glaucoma had no significance without the adjustment. The authors used two models of adjustments: adjustments for demographic factors and for the selfreport of the general health condition. The model in which glaucoma and depression were adjusted for the demographic factors, the association of glaucoma and depression, was significant. The model with adjustment for the general health condition found no significant correlation with glaucoma and depression. We can calculate that PHQ-9 is not the instrument of choice for the assessment of depression in glaucoma patients. On the other hand, Furukawa reported (Furukawa 2010) PHQ-9 as an instrument with excellent psychometric properties but with substantial heterogeneity in screening validity, which could not be explained.
There Table 1 ). Table 1 recapitulates the comparison between reviewed studies based on the assessment of depression, format of rating scales for depression, format of glaucoma assessment and the total number of the participants with the share of glaucoma patients (e.g. Table 1 ). Only one study used clinician-rated scales (HDRS and MADRS) for the assessment of depression in glaucoma patients (Cumurcu et al. 2006) . Most of the studies used objective visual tests for glaucoma assessment. Only in two studies glaucoma was assessed by self-report method (Ermudugolla et al. 2013 , Wang et al. 2012 ). In the first study, there was no evidence for elevated rates of depression in glaucoma (Ermudugolla et al. 2013 ). The total number of participants and the number of glaucoma patients varied widely among reviewed studies (e.g. Table 1 ). The total number of participants ranged from 6760 to 86. The range of glaucoma patients varied from 10 to 453. In one study the number of glaucoma patients was unknown (Kiely et al. 2013) . Some of the studies were performed only with the glaucoma patients (Gothwal et al. 2014 , Agorastos et al. 2013 , while others had combination of patients with visual impairment, control group. One of the issues which could have influenced the results was the range of glaucoma patients in the study.
Management of patients who suffer from glaucoma and depression
The aging of population, the increase in various comorbidities, the various available medications and the organization of health care pose a great challenge for clinicians in the management of chronic patients today.
By focusing only on the treatment of glaucoma, comorbidities are often neglected. Depression as a comorbid condition deteriorates the health of the patients more than depression alone or more than other chronic conditions, alone or in combination of different chronic diseases without depression (Moussavi et al. 2007) . Chronic conditions such as glaucoma may be associated with depression due to the age of patients (Jeong et al. 2006 , Kong et al. 2014 , prolonged daily use of antiglaucoma medications, limitation of daily activities, limitation of family and working roles (Guedes et al. 2012) .
The antiglaucoma medication is mostly topical application. The possibilities of systematic adverse effects are uncommon but they are still possible (Jeong et al. 2016 ). For example, the caution with regard to use of ocular beta-blockers was recommended in the case of depression, asthma and heart disease. However, recent studies did not find any correlation between beta-blocker use and depression (Wilson et al. 2002) . The recent studies have also suggested that phenylephrine eye drops had no clinically relevant effects on the heart rate or blood pressure as was previously suggested (Stavert et al. 2015) .
The topical administration of antiglaucoma medications, on the other hand, has very common topical side effects (Guedes et al. 2012 , Servat & Bernardino 2011 , Park et al. 2013 ) such as eyelid dermatitis, lacrimal system scarring, ocular discomfort upon instillation, conjunctival inflammation and conjunctival epithelium changes, corneal surface and endothelial impairment, blurred vision, a stinging sensation etc. The patients diagnosed with glaucoma during the period when the symptoms of visual field and visual function loss had not still been developed, could only experience the disturbing side effects of antiglaucoma therapy. As a result, some of the early diagnosed glaucoma patients might give up on therapy. The initial education of patients regarding the possibilities of side effects of the antiglaucoma therapy and the severe consequences of nonadherence to it is very important (Park et al. 2013 ).
The price of medications, the difficulties with administration and dosing schedule might contribute to poor compliance, worsening IOP, and consequently depression. The patient is in vicious circle.
The different situation with the same result appears in patients with good compliance, sometimes multiple ophthalmological therapy (surgery and multiple medications), regular follow-ups, with the result of advanced glaucoma and VFL with the respond of depression (Gothwal et al. 2014 ).
Administration of psychiatric medication can cause glaucoma (Jeong et al. 2016 ). Tricyclic antidepressants can lead to closed-angle glaucoma because of anticholinergic activity. Because of epinephrine receptor blockade, some of the antipsychotic drugs can also cause closed-angle glaucoma. Selective serotonin inhibitors and benzodiazepines can generate in closed-angle glaucoma. Long-term use of selective serotonin reuptake inhibitors (SSRI), which are the most prescribed type of medication for depression, does not significantly influence the risk of POAG and PACG (Chen et al. 2015) . One of the future possibilities in the management of comorbidity of glaucoma and depression is MLT, as it was described in the papers of Agorastos and Huber (Agorastos & Huber 2010), and Tosini et al. .
The character of depression with the hopelessness and pessimism may cause poor compliance and withdrawal of the therapy (Jeong et al. 2016) .
Besides the standard therapy of glaucoma, topical antiglaucoma medications and surgery, novel approaches such as melatonin (Agorastos & Huber 2011 ), endocannabinoid system (Cairns et al. 2016) , and bone-marrow mesenchymal stem cell (Roubeix et al. 2015) should be explored.
Cognitive deficits are often comorbid with depression (Joeng et al. 2016 ). Due to cognitive deficit the patients are not able to comprehend the character of glaucoma and the necessity of adherence to the therapy which leads to worsening of glaucoma and blindness.
The management of the patients with comorbidity of glaucoma and depression should be organized on the basis of a multidisciplinary approach (Jeong et al. 2016 ). An ophthalmologist has to recognize and take into account a state of depression when the treatment plan is made (Moussavi et al. 2007 ).
The organization of health care in the case of subspecialist glaucoma ambulance is an important factor in the management of glaucoma patients (the time for the review; education about the characteristics of glaucoma, possibilities and side effects of treatment; the real role of glaucomatologyst, the role of a subspecialty nurse). The next step should be the involvement of a multidisciplinary team consisting of psychologists, psychiatrists and rehabilitation therapists (Rovner et al. 2014 ).
Conclusion
The results presented in this review indicated that glaucoma is accompanied by depression in the majority of analyzed studies. The rating scales used in assessing depression in studies analyzed in this review had different purposes and different formats. The questionable is connection of formats of instruments used in the studies (self-reporting or clinician-reporting) and assessments or no assessment of depression. Besides the issues of different instruments, formats of assessments and the number of participants in the studies, subjective experience of patients and physicians should be taken into account when assessing the depression in glaucoma patients (Wang et al. 2012 ). The reviewed studies did not analyze therapy options of glaucoma patients with depression. The treatment of comorbidity of glaucoma and depression should not depend only on ophthalmologist or psychiatrist, the assessment of treatment should be multidisciplinary. New approaches, such as MLT administration, should be taken into account in the management of glaucoma patients with depression. The management of glaucoma and depression should be comprehended as a public-health issue because of epidemiological data regarding the rising prevalence of both chronic diseases worldwide.
